Welcome to our dedicated page for BTX news (Ticker: BTX), a resource for investors and traders seeking the latest updates and insights on BTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BTX's position in the market.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) has appointed Dr. Roger Sidhu as Chief Medical Officer, effective September 20, 2021. Dr. Sidhu brings extensive R&D experience, including in late-stage clinical development for various cancers. His leadership is expected to guide the company through a critical phase, enhancing its mRNA-based gene editing and cellular reprogramming initiatives. Brooklyn's primary program, IRX-2, is in Phase 2B for head and neck cancer, following promising results in earlier trials. The company also focuses on developing therapies for blood disorders and genetic diseases.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) held a Shareholder Update Call on September 20, 2021, where CEO Howard J. Federoff and guest Matt Angel discussed the company's focus on cytokine, gene editing, and cell therapy for treating cancer and genetic disorders. Key highlights included the use of iMSCs for addressing poor bone marrow transplants, plans for gene editing to target solid tumors and monogenic disorders, and advancements in mRNA strategies to enhance therapeutic efficacy. Brooklyn's lead program, IRX-2, showed overall survival benefits in Phase 2A trials for head and neck cancer.
Brooklyn ImmunoTherapeutics (BTX) announced a shareholder update conference call scheduled for September 20, 2021. The call, led by CEO Dr. Howard Federoff, will focus on the company’s mRNA cell-engineering platform, which is based on exclusive technology licensed from Factor Bioscience. Participants must pre-register for the call, while others can join via provided dial-in numbers. Brooklyn's lead program, IRX-2, is a cytokine therapy currently in Phase 2B trials for head and neck cancer, following a positive Phase 2A trial showing survival benefits.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced the opening of its new mRNA Cleanroom facility in Cambridge, Massachusetts, shared with Factor Bioscience. CEO Howard J. Federoff highlighted the facility’s importance for R&D operations and its role in developing treatments for cancer, sickle cell, and ARDS. The facility offers 2,700 sq. ft. of lab space and aims to create seven R&D jobs. Brooklyn's leading program, IRX-2, is in Phase 2B trials for head and neck cancer, showing promising results in earlier phases.
BROOKLYN, N.Y., Aug. 20, 2021 – Brooklyn ImmunoTherapeutics (NYSE American: BTX) convened its 2021 Annual Meeting of Stockholders but had to adjourn it without conducting business due to lacking the required quorum of 83% of shares outstanding. The meeting is rescheduled for September 3, 2021, to allow stockholders more time to vote. A proxy solicitor has been engaged to assist in obtaining the necessary votes. Stockholders are urged to vote by September 2, 2021. The company continues to advance its clinical programs, including its IRX-2 therapy for head and neck cancer.
BROOKLYN ImmunoTherapeutics, focusing on cytokine and gene editing therapies, provided updates from a shareholder call on August 19, 2021. Key highlights include the integration of Novellus, strategic planning for pipeline programs, and ongoing development of IRX-2, aimed at treating head and neck cancer, with topline data expected in H1 2022. The company has approximately $25 million in cash to support growth and recruitment. Additionally, they are exploring new mesenchymal stem cell products and gene editing for monogenic diseases.
BROOKLYN, N.Y., Aug. 16, 2021 – Brooklyn ImmunoTherapeutics (NYSE American: BTX) has announced a shareholder update conference call scheduled for August 19, 2021, at 4:30 p.m. ET. The call will include a live Q&A session and is accessible via registration or direct dial numbers. Brooklyn focuses on cytokine and gene editing/cell therapies aimed at treating various conditions, with its leading program, IRX-2, demonstrating potential in Phase 2A trials for head and neck cancer. Interested participants can submit questions before the call.
Brooklyn ImmunoTherapeutics (BTX) reported its Q2 2021 financial results, highlighting a significant net loss of $(27.8 million compared to $(3.1 million in Q2 2020. The company raised nearly $51 million through equity line sales to enhance its mRNA gene editing and cell therapies. The acquisition of Novellus Therapeutics was completed in July 2021, allowing Brooklyn to utilize advanced MSC therapies. Operating expenses surged to $10.1 million, primarily due to increased R&D activities. Brooklyn holds approximately $25 million in cash after the Novellus deal, with expectations to fund operations through the end of 2023.
Brooklyn ImmunoTherapeutics, focused on cytokine and gene editing therapies, will present at the SNN Virtual Investor Conference from August 17-19, 2021. CEO Howard J. Federoff will deliver a corporate overview on August 18 at 12:00 PM ET. Investors can schedule one-on-one meetings during the event. Brooklyn's lead program, IRX-2, is in Phase 2B trials for head and neck cancer, showing promise in previous trials. The company is advancing multiple therapies for various conditions, including cancer and rare genetic diseases. More information can be found on their official website.
FAQ
What is the market cap of BTX (BTX)?
